Premium
Complications in patients after intravitreal injection of bevacizumab
Author(s) -
Shima Chiharu,
Sakaguchi Hirokazu,
Gomi Fumi,
Kamei Motohiro,
Ikuno Yasushi,
Oshima Yusuke,
Sawa Miki,
Tsujikawa Motokazu,
Kusaka Shunji,
Tano Yasuo
Publication year - 2008
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1600-0420.2007.01067.x
Subject(s) - medicine , bevacizumab , chemosis , ophthalmology , intraocular pressure , intravitreal administration , surgery , retinal , chemotherapy
. Purpose: To report complications in patients after intravitreal injection of bevacizumab to treat ocular diseases associated with vascular endothelial growth factor. Methods: We retrospectively reviewed the systemic and ocular complications that developed within 2 months of each intravitreal injection of bevacizumab in 707 patients (1300 injections) with intraocular neovascularization or macular oedema. Results: Nine ocular (1.27%) and eight systemic (1.13%) complications occurred in 707 patients. The ocular complications included corneal abrasion ( n = 2), chemosis ( n = 2), lens injury ( n = 1), ocular inflammation ( n = 2), retinal pigment epithelial tear ( n = 1) and acute vision loss ( n = 1). The systemic complications included cerebral infarction ( n = 1), elevation of systolic blood pressure ( n = 2), facial skin redness ( n = 1), itchy diffuse rash ( n = 1) and menstrual irregularities ( n = 3). Conclusion: Intravitreal injection of bevacizumab may cause systemic or ocular complications. Caution is advised when considering intravitreal injection of this drug.